ALK and non-small cell lung carcinoma: In conclusion, this study demonstrated that the administration of ceritinib in the front‐line for the treatment of ALK‐positive NSCLC had superior efficacy than crizotinib, in which a better control of systemic progression could be attributed to this finding.